Killing drug-resistant melanoma requires combination therapy

This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors …

Get more stuff like this
in your inbox

From anti-aging to the search for alien life, we promise to never bore.